Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 6/20 | 0.50 |
| ▸ | METAP2 | P50579 | 3/20 | 0.48 |
| ▸ | CBFB | Q13951 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.40 |
| ▸ | TACR2 | P21452 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
| ▸ | GCGR | P47871 | 1/20 | 0.38 |
| ▸ | RHOC | P08134 | 1/20 | 0.38 |
| ▸ | RHOA | P61586 | 1/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5650763 | 0.91 | FLT3 (0.51) | FLT3METAP2CBFBEGLN1RHOC | |
| SCHEMBL5651705 | 0.90 | FLT3 (0.50) | FLT3METAP2CBFBPPARDEGLN1 | |
| SCHEMBL5649037 | 0.89 | METAP2 (0.50) | FLT3METAP2CBFBMRGPRX4DYRK1A | |
| SCHEMBL5650786 | 0.88 | METAP2 (0.47) | FLT3METAP2CBFBPPARDTACR2 | |
| SCHEMBL5650711 | 0.88 | FLT3 (0.47) | FLT3METAP2CBFBRHOCRHOA | |
| SCHEMBL5652819 | 0.86 | FLT3 (0.54) | FLT3CBFBEGLN1RHOCRHOA | |
| SCHEMBL5651383 | 0.86 | FLT3 (0.48) | FLT3METAP2PPARDTACR2TACR1 | |
| SCHEMBL5651055 | 0.85 | FLT3 (0.68) | FLT3METAP2 | |
| SCHEMBL5651066 | 0.83 | FLT3 (0.61) | FLT3METAP2GCGR | |
| SCHEMBL5653019 | 0.81 | METAP2 (0.46) | FLT3METAP2CBFBTACR2TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220769-B2 | Azolylbenzamides and analogues and their use for treating osteoporosis | NIKEM RESEARCH S.R.L. (IT) | 2007-05-22 | — | — | US | disclosed |
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | 3-V BIOSCIENCES, INC. | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | NR0B2, NR0B1, NCOR1 | FLT3 1968/4885METAP2 3311/4885CBFB 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.